Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
Date:11/6/2009

ated in order to integrate the virus in the panoply of agents used for sarcoma treatment."

"These results are consistent with what we observed on an interim basis when we reported data on the first 16 patients back in June 2008," said Dr. Brad Thompson, President and CEO of Oncolytics. "It is encouraging that we are observing stable disease in a range of sarcomas and the clinical benefit is not isolated to any specific type."

A copy of the poster will be available on the Oncolytics website today.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at the CTOS meeting with respect to REOLYSIN; the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actua
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... YORK , Aug. 27, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent A ... form covalent bonds with metal ions, thereby forming ... that some metal-ions have on chemical processes, formulations, ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 According to ... continues to reshape the look and feel of markets ... demand for higher-quality ingredients will push for more branded, ... market have experienced strong market growth in the last ... in their food and cosmetics to fit a more ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... ... Communications and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and ... of unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated ...
... Calif., June 17 Oclaro, Inc. (Nasdaq: ... Fluorescence Filter for biomedical and analytical instrumentation markets. Oclaro ... range of biomedical and analytical applications, including clinical diagnostics, ... The latest offerings from the Oclaro filter portfolio are ...
... BioEnergy International, LLC (BioEnergy), a ... biochemicals and biofuels, announces the formation of Myriant ... biobased chemicals business and intellectual property. BioEnergy ... its 110 million gallon per day ethanol plant ...
Cached Biology Technology:San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4Oclaro(TM) Hits Milestone With Clarity(TM) Fluorescence Filters 2Oclaro(TM) Hits Milestone With Clarity(TM) Fluorescence Filters 3BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2
(Date:8/27/2014)... of fishing traps are lost or abandoned each year ... derelict traps, which continue to catch fish, crabs, and ... losses to habitat, fisheries, and the watermen who depend ... a newly published NOAA study. , The report, published ... first of its kind to examine the derelict fish ...
(Date:8/27/2014)... Complex of fires had consumed 24,939 acres of land ... as of eight hours ago. , Lightning strikes ... of the Klamath National Forest when a thunderstorm passed ... three of those fires are now 100 percent contained. ... their size at containment: Delta, 150 acres; Sutcliffe, 27 ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2Happy Camp and July Fire Complexes in California 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... and American Board of Internal Medicine (ABIM) announce the ... performance evaluation tools for blood specialists. , ... ABIM certification, ASH and ABIM have co-developed the Hematology ... to complete their practice performance assessment requirement for recertification. ...
... research project which could revolutionise the diagnosis and treatment ... four-year project, the results of which are now being ... means of identifying the two most deadly forms of ... for practitioners. , The implications for improving children's health ...
... to ferns to create a novel energy scavenging device that ... provide a method for powering micro and nano devices with ... works," said Michel Maharbiz, assistant professor of electrical engineering and ... the device. "If you build these things they will move. ...
Cached Biology News:New tool helps blood specialists improve patient care 2Hope for major advance in fighting world killer disease 2Hope for major advance in fighting world killer disease 3Ferns provide model for tiny motors powered by evaporation 2
Tachykinin (H-2)...
Human BMP 2 Construction Kit provides antigen affinity purified polyclonal capture and tracer antibodies, and antigen standard for development of approximately ten microplate assays....
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... utilizies CTI Molecular Imaging's proprietary Focus™ detector ... volume as the R4. The microPET ... any commerically avaiable PET scanner. Focus ... of any scinitallor based PETsystems. The ...
Biology Products: